|
Dr. Berkowitz earned his B.A. M.D. and Ph.D. from Columbia University and trained at the National Cancer Institute in medical oncology. Prior to founding HaptoGuard he was a consultant to a variety of biotechnology companies in Israel including Predix Pharmaceuticals IDGene and Teva. He was previously Vice President of Clinical Development at IMPATH Inc. a NASDAQ-traded cancer information company where he co-developed a division IMPATH Predictive Oncology focused on biopharmaceutical partnerships supporting the discovery and development of cancer-related targeted diagnostics and therapeutics. Prior to IMPATH Dr. Berkowitz was the founder of Physician Choice Inc. a contract research organization specializing in pharmacoeconomics and outcomes. | 